{{Rsnum
|rsid=1079598
|Gene=DRD2
|Chromosome=11
|position=113425552
|Orientation=minus
|GMAF=0.2126
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=DRD2
}}{{PharmGKB
|RSID=rs1079598
|Name_s=
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:20714340
|Annotation=Risk or phenotype-associated allele: C. Phenotype: The C allele was associated with weight gain of at least 7% in schizophrenia patients treatment with clozapine or olanzapine. Study size: 206. Study population/ethnicity: European american; African American; German; Schizophrenia. Significance metric(s): OR = 3.44 (CI: 1.46-8.11). Type of association: PD.
|Drugs=clozapine; olanzapine
|Drug Classes=ANTIPSYCHOTICS
|Diseases=Weight gain
|Curation Level=Curated
|PharmGKB Accession ID=PA165374658
}}

{{PMID Auto
|PMID=21247255
|Title=Dopaminergic system genes in childhood aggression: Possible role for DRD2
}}

{{PMID Auto
|PMID=19793394
|Title=Haplotype frequencies at the DRD2 locus in populations of the East European Plain.
|OA=1
}}

{{PMID Auto
|PMID=20021678
|Title=Evaluation of self-reported ethnicity in a case-control population: the stroke prevention in young women study.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}